TTR and restrictive cardiomyopathy: The only drug proved to be associated with prognostic benefit in ATTR-CA is tafamidis, which is a highly specific drug that targets the circulating TTR protein and stabilizes the TTR tetramer to prevent dissociation into amyloidogenic monomers that deposit in the myocardium, causing an infiltrative and restrictive cardiomyopathy.